198 related articles for article (PubMed ID: 12747884)
21. Megakaryoblastic leukemia and Down's syndrome: a review.
Zipursky A; Peeters M; Poon A
Pediatr Hematol Oncol; 1987; 4(3):211-30. PubMed ID: 2978961
[TBL] [Abstract][Full Text] [Related]
22. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.
Shimada A; Xu G; Toki T; Kimura H; Hayashi Y; Ito E
Blood; 2004 Jan; 103(1):366. PubMed ID: 14684662
[No Abstract] [Full Text] [Related]
23. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome.
Taub JW; Mundschau G; Ge Y; Poulik JM; Qureshi F; Jensen T; James SJ; Matherly LH; Wechsler J; Crispino JD
Blood; 2004 Sep; 104(5):1588-9. PubMed ID: 15317736
[No Abstract] [Full Text] [Related]
24. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
[TBL] [Abstract][Full Text] [Related]
25. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
[TBL] [Abstract][Full Text] [Related]
26. Expression of erythroid-specific genes in megakaryoblastic disorders.
Ito E; Kasai M; Toki T; Arai K; Yokoyama M
Leuk Lymphoma; 1996 Nov; 23(5-6):545-50. PubMed ID: 9031085
[TBL] [Abstract][Full Text] [Related]
27. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
McElwaine S; Mulligan C; Groet J; Spinelli M; Rinaldi A; Denyer G; Mensah A; Cavani S; Baldo C; Dagna-Bricarelli F; Hann I; Basso G; Cotter FE; Nizetic D
Br J Haematol; 2004 Jun; 125(6):729-42. PubMed ID: 15180862
[TBL] [Abstract][Full Text] [Related]
28. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
29. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation.
Magalhães IQ; Splendore A; Emerenciano M; Córdoba MS; Córdoba JC; Allemand PA; Ferrari I; Pombo-de-Oliveira MS
J Pediatr Hematol Oncol; 2005 Jan; 27(1):50-2. PubMed ID: 15654280
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome.
Hirose Y; Kudo K; Kiyoi H; Hayashi Y; Naoe T; Kojima S
Leukemia; 2003 Nov; 17(11):2250-2. PubMed ID: 12931214
[No Abstract] [Full Text] [Related]
31. GATA1--a player in normal and leukemic megakaryopoiesis.
Hitzler JK
Pediatr Res; 2002 Dec; 52(6):831. PubMed ID: 12438656
[No Abstract] [Full Text] [Related]
32. GATA1 in normal and malignant hematopoiesis.
Crispino JD
Semin Cell Dev Biol; 2005 Feb; 16(1):137-47. PubMed ID: 15659348
[TBL] [Abstract][Full Text] [Related]
33. Improved outcome of acute myeloid leukaemia in Down's syndrome.
Craze JL; Harrison G; Wheatley K; Hann IM; Chessells JM
Arch Dis Child; 1999 Jul; 81(1):32-7. PubMed ID: 10373130
[TBL] [Abstract][Full Text] [Related]
34. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome.
Harigae H; Xu G; Sugawara T; Ishikawa I; Toki T; Ito E
Blood; 2004 Apr; 103(8):3242-3. PubMed ID: 15070711
[No Abstract] [Full Text] [Related]
35. A leukemogenic twist for GATA1.
Look AT
Nat Genet; 2002 Sep; 32(1):83-4. PubMed ID: 12172549
[No Abstract] [Full Text] [Related]
36. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
[TBL] [Abstract][Full Text] [Related]
37. Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome.
Groet J; Mulligan C; Spinelli M; Serra A; McElwaine S; Cotter FE; Dagna-Bricarelli F; Saglio G; Basso G; Nizetic D
Blood; 2005 Sep; 106(5):1887-8. PubMed ID: 16113234
[No Abstract] [Full Text] [Related]
38. Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.
Ono R; Hasegawa D; Hirabayashi S; Kamiya T; Yoshida K; Yonekawa S; Ogawa C; Hosoya R; Toki T; Terui K; Ito E; Manabe A
Eur J Pediatr; 2015 Apr; 174(4):525-31. PubMed ID: 25266042
[TBL] [Abstract][Full Text] [Related]
39. High leukaemia cure rate in Down's syndrome explained.
Bradbury J
Lancet Oncol; 2005 Mar; 6(3):134. PubMed ID: 15759357
[No Abstract] [Full Text] [Related]
40. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
